Arbutus Biopharma ABUS Stock
Arbutus Biopharma Price Chart
Arbutus Biopharma ABUS Financial and Trading Overview
| Arbutus Biopharma stock price | 3.35 USD |
| Previous Close | 2.47 USD |
| Open | 2.47 USD |
| Bid | 0 USD x 2900 |
| Ask | 0 USD x 1800 |
| Day's Range | 2.39 - 2.47 USD |
| 52 Week Range | 1.85 - 3.15 USD |
| Volume | 691.53K USD |
| Avg. Volume | 724.82K USD |
| Market Cap | 405.37M USD |
| Beta (5Y Monthly) | 2.249647 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.38 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.4 USD |
ABUS Valuation Measures
| Enterprise Value | 270.72M USD |
| Trailing P/E | N/A |
| Forward P/E | -4.5185184 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 12.2374935 |
| Price/Book (mrq) | 2.7981653 |
| Enterprise Value/Revenue | 8.173 |
| Enterprise Value/EBITDA | -3.968 |
Trading Information
Arbutus Biopharma Stock Price History
| Beta (5Y Monthly) | 2.249647 |
| 52-Week Change | -8.95% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 3.15 USD |
| 52 Week Low | 1.85 USD |
| 50-Day Moving Average | 2.64 USD |
| 200-Day Moving Average | 2.56 USD |
ABUS Share Statistics
| Avg. Volume (3 month) | 724.82K USD |
| Avg. Daily Volume (10-Days) | 501.87K USD |
| Shares Outstanding | 166.13M |
| Float | 124.36M |
| Short Ratio | 7.58 |
| % Held by Insiders | 25.21% |
| % Held by Institutions | 32.79% |
| Shares Short | 4.25M |
| Short % of Float | 3.40% |
| Short % of Shares Outstanding | 2.56% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:5 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -211.41% |
| Operating Margin (ttm) | -210.082% |
| Gross Margin | -154.25% |
| EBITDA Margin | -205.95% |
Management Effectiveness
| Return on Assets (ttm) | -20.31% |
| Return on Equity (ttm) | -45.21% |
Income Statement
| Revenue (ttm) | 33.13M USD |
| Revenue Per Share (ttm) | 0.22 USD |
| Quarterly Revenue Growth (yoy) | -46.80% |
| Gross Profit (ttm) | -45389000 USD |
| EBITDA | -68223000 USD |
| Net Income Avi to Common (ttm) | -70030000 USD |
| Diluted EPS (ttm) | -0.45 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 146.73M USD |
| Total Cash Per Share (mrq) | 0.88 USD |
| Total Debt (mrq) | 2.12M USD |
| Total Debt/Equity (mrq) | 1.47 USD |
| Current Ratio (mrq) | 6.077 |
| Book Value Per Share (mrq) | 0.872 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -83276000 USD |
| Levered Free Cash Flow (ttm) | -42157000 USD |
Profile of Arbutus Biopharma
| Country | United States |
| State | PA |
| City | Warminster |
| Address | 701 Veterans Circle |
| ZIP | 18974 |
| Phone | 267 469 0914 |
| Website | https://www.arbutusbio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 96 |
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-161, an oral HBV RNA destabilizer; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate AB-729. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Q&A For Arbutus Biopharma Stock
What is a current ABUS stock price?
Arbutus Biopharma ABUS stock price today per share is 3.35 USD.
How to purchase Arbutus Biopharma stock?
You can buy ABUS shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Arbutus Biopharma?
The stock symbol or ticker of Arbutus Biopharma is ABUS.
Which industry does the Arbutus Biopharma company belong to?
The Arbutus Biopharma industry is Biotechnology.
How many shares does Arbutus Biopharma have in circulation?
The max supply of Arbutus Biopharma shares is 194.39M.
What is Arbutus Biopharma Price to Earnings Ratio (PE Ratio)?
Arbutus Biopharma PE Ratio is now.
What was Arbutus Biopharma earnings per share over the trailing 12 months (TTM)?
Arbutus Biopharma EPS is -0.38 USD over the trailing 12 months.
Which sector does the Arbutus Biopharma company belong to?
The Arbutus Biopharma sector is Healthcare.
Arbutus Biopharma ABUS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17146.39 USD — |
-1.36
|
6.49B USD — | 17133.29 USD — | 17467.35 USD — | — - | 6.49B USD — |
| NASDAQ Global Select Market Com NQGS | 8390.08 USD — |
-1.34
|
— — | 8380.89 USD — | 8543.96 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4158.72 USD — |
+0.66
|
— — | 4155.12 USD — | 4202.15 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 924.57 USD — |
+0.11
|
— — | 923.44 USD — | 934.48 USD — | — - | — — |
| NASDAQ Composite Total Return I XCMP | 21024.86 USD — |
-1.19
|
— — | 20973.2 USD — | 21382.13 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4157.43 USD — |
+0.21
|
— — | 3927.42 USD — | 4157.43 USD — | — - | — — |
- {{ link.label }} {{link}}